The US pharmaceutical company Merck & Co. is working with DAIICHI SANKYO on three potential cancer therapies.
The two companies agreed to jointly develop and market the drug candidates Atritumab Deruxtecan, Ifinatamab Deruxtecan and Raludotatug Deruxtecan worldwide. The deal is worth up to $22 billion and will weigh on Merck’s fourth quarter.
The DAIICHI SANKYO share recently gained 14.42 percent to 4,095 yen in Tokyo. Merck & Co. shares are currently up 0.27 percent at $100.70 in pre-market trading on the NYSE.
(Dow Jones Newswires)
Selected leverage products on DAIICHI SANKYO
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on DAIICHI SANKYO
The leverage must be between 2 and 20
Advertising
Image sources: Katherine Welles / Shutterstock.com, Adam Michal Ziaja / Shutterstock.com